Jun 13, 2023 / 08:20PM GMT
Nathan Allen Rich - Goldman Sachs Group, Inc., Research Division - Research Analyst
Great. Well, good afternoon, everyone. Thanks so much for joining us for our first afternoon session. My name is Nathan Rich, I cover the generic pharma space for Goldman Sachs. Very pleased to have Viatris up here with us. I'll do some quick introductions and then we can jump into the Q&A.
So to my right, Scott Smith, new Chief Executive Officer; in the center, Rajiv Malik, President; and Sanjeev Narula, CFO. So thank you guys for joining us. Really appreciate you being here.
Scott Andrew Smith - Viatris Inc. - CEO & Director
Thank you.
Questions and Answers:
Nathan Allen Rich - Goldman Sachs Group, Inc., Research Division - Research AnalystGreat. Well, Scott, new to the company. So you joined the Board in December, became CEO in April. Can you maybe just talk about what attracted you to Viatris and what your initial impressions of the company has been so far?
Scott Andrew Smith -